XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

This trial compares two treatment approaches before surgery for people with locally advanced rectal cancer: the standard chemotherapy regimen (XELOX) alone versus XELOX combined with cadonilimab, an immunotherapy drug. Researchers want to find out if adding immunotherapy shrinks the tumor more effectively before surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with rectal cancer located 5–15 cm from the anal opening, and it is locally advanced - Your tumor is classified as mismatch repair proficient (pMMR) — a specific lab finding - You have not received any prior treatment - You are in good health (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have had prior chemotherapy, radiation, or surgery for this cancer - Your blood, kidney, or liver tests are outside normal ranges - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.